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Abstract
Currently available microbubbles used for ultrasound imaging and therapeutics are limited to 
intravascular space due to their size distribution in the micron range. Phase-change contrast agents 
(PCCAs) have been proposed as a means to overcome this limitation, since droplets formed in the 
hundred nanometer size range might be able to extravasate through leaky microvasculature, after 
which they could be activated to form larger highly echogenic microbubbles. Existing PCCAs in 
the sub-micron size range require substantial acoustic energy to be vaporized, increasing the 
likelihood of unwanted bioeffects. Thus, there exists a need for PCCAs with reduced acoustic 
activation energies for use in imaging studies. In this article, it is shown that decafluorobutane, 
which is normally a gas at room temperature, can be incorporated into metastable liquid sub-
micron droplets with appropriate encapsulation methods. The resulting droplets are activatable 
with substantially less energy than other favored PCCA compounds. Decafluorobutane 
nanodroplets may present a new means to safely extend ultrasound imaging beyond the vascular 
space. (E-mail: padayton@bme.unc.edu)
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In the past two decades, gas-filled contrast agents for ultrasound (US) have been extensively 
explored and show promising results in applications ranging from echocardiography to 
molecular imaging of highly-vascularized tumors (Lindner 2009; Sboros and Tang 2010; 
Staub et al. 2010; Gessner and Dayton 2010; Wilson and Burns 2010). FDA-approved 
microbubble contrast agents (MCAs) are commonly produced with the majority of the 
population between 1 and 5 μm in diameter to allow for safe passage through the circulatory 
system and provide significant contrast for imaging. Beyond imaging, microbubbles have 
demonstrated substantial potential for use in therapeutic applications such as drug delivery, 
gene delivery and thrombolysis (Ferrara et al. 2007; Hitchcock and Holland 2010; Sirsi and 
Borden 2009; Stride and Coussios 2010; Tinkov et al. 2009). Many tumor types exhibit 
characteristically permeable vasculature, with endothelial gaps typically between 200–600 
nm and show poor lymphatic clearance, also known as the enhanced permeability and 
retention (EPR) effect (Hobbs et al. 1998; Campbell 2006; Torchilin 2010). A gas-filled 
contrast agent small enough to extravasate into tumor interstitium would ultimately be much 
less echogenic than commonly studied MCAs in the 1–5 μm range and would provide 
limited US contrast (Kaya et al. 2010). Therefore, an agent capable of clearing inter-
endothelial gaps and subsequently being transformed into a gas-filled MCA in the 1–5 μm 
range would have unique possibilities. Nanoemulsions have been used in the past as drug 
delivery agents in conjunction with ultrasound-mediated localized delivery via radiation 
force/acoustic streaming (Dayton and Matsunaga 2006). Rapoport et al. (2009b) have 
illustrated the concept of a nanoemulsion that is small enough to accumulate at an interstitial 
target site and can then be converted to the gaseous state through the application of 
ultrasonic energy and used to aid in therapeutic dose delivery.
The application of acoustic droplet vaporization (ADV) is a potential method of designing a 
contrast agent that can exploit the EPR effect and provide imaging contrast in tumor 
extravascular space. ADV, the transition of a superheated liquid droplet into gas, was 
described for therapeutic and diagnostic use over a decade ago (Apfel 1998; Quay 1996). It 
has since been used in studies with a variety of proposed applications including aberration 
correction (Kripfgans et al. 2002; Haworth et al. 2008), occlusion therapy (Kripfgans et al. 
2005; Zhang et al. 2010), therapeutic drug delivery (Rapoport et al. 2009b; Fabiilli et al. 
2010a, 2010b), and high-intensity focused ultrasound (HIFU) and lithotripsy-based 
nucleation agents to enhance thermal delivery and cavitation-based bioeffects (Miller et al. 
2000; Zhang and Porter 2010). While not fully understood, many of the physical 
mechanisms involved in ADV are in the process of being described and modeled (Ye and 
Bull 2004, 2006; Evans et al. 2006; Qamar et al. 2010). In brief, the vaporization of a liquid 
droplet depends primarily on the properties of the surrounding fluid (viscosity, ambient 
temperature and pressure), the droplet diameter and the energy introduced into the system 
(heating, mechanical energy). Often a lipid or polymer shell is used to both stabilize the 
droplet from coalescence and to increase the Laplace pressure exerted on it, allowing for 
droplets of larger size and/or lower boiling point to remain in a liquid state. Most studies 
involving ADV-based liposomal nano/micro-emulsions have used either stabilized or 
superheated liquids in the perfluorocarbon (PFC) family, as many have boiling points near 
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physiologic temperatures and are similar to commonly-used MCA perfluorocarbons that 
have significant advantages in imaging applications with less toxicity at the small volumes 
used (Mattrey 1994). The most common PFCs used to date, dodecafluoropentane (DDFP) 
and perfluorohexane (PFH), are liquids at room temperature. When encased in lipid or 
polymer shells, nano/micro-emulsions of DDFP and PFH are able to stay in solution at body 
temperature and can be activated by additional energy input.
Many studies have reported the variety of effects that environmental and test conditions such 
as ambient temperature (Fabiilli et al. 2009; Zhang and Porter 2010), fluid viscosity (Lo et 
al. 2006), ultrasound frequency, peak negative pressure and pulse length (Kripfgans et al. 
2000; Giesecke and Hynynen 2003; Lo et al. 2007; Fabiilli et al. 2009; Schad and Hynynen 
2010) can have on the vaporization threshold for a particular droplet or droplet emulsion. 
Other studies have shown that incorporation of nanoparticles may actually decrease the 
threshold, which is promising for therapeutic applications (Matsuura et al. 2009). Reports of 
higher interstitial pressure in the abnormal tumor microenvironment may also impact the 
success of phase-change contrast agents vaporizing in tumor interstitium (Ferretti et al. 
2009). It has been demonstrated by these studies that raising ambient pressure increases the 
vaporization threshold while raising temperature decreases it. The inverse relationship 
between the vaporization threshold and PFC droplet diameter is also well demonstrated. 
Therefore, an agent with sufficient stability to extravasate into the extracellular space, yet 
labile enough to be vaporized at sufficiently low acoustic intensities so as to not induce 
unwanted bioeffects would be optimal. Most studies of phase-change contrast agents to date 
have shown that DDFP droplets near the desired size range vaporize with the least energy 
input compared with alternative compounds. The input pressure needed to vaporize them 
can be lowered even further by altering the duration of the excitation acoustic pulse (Lo et 
al. 2007). By using ultrasound frequencies above 1 MHz and pulse-lengths in the 
millisecond range, micron-sized droplets can be vaporized with pressures considered safe 
for diagnostic procedures (Fabiilli et al. 2009). However, data suggest that the vaporization 
of sub-micron droplets may require substantially more energy. Thus, sub-micron ADV, 
which requires high mechanical indices, would enhance the possibility of bioeffects, an 
undesirable side effect for imaging-only applications. Choosing alternative lower boiling-
point PFCs could lower the vaporization threshold for sub-micron droplets, although they 
then have the potential to be relatively unstable compared with their higher boiling-point 
counterparts. In some applications, such as thermal ablation enhancement, droplet stability 
through a range of temperatures above 37°C may be a priority over low vaporization 
thresholds (Zhang and Porter 2010). Kawabata et al. (2005) have proposed that to increase 
stability, the lower boiling-point PFC could be used as a “volatile agent” in mixture with a 
“non-volatile agent” of a higher boiling point to produce agents with a lowered threshold.
In this article, it is demonstrated that decafluorobutane (DFB) may achieve the desired low 
vaporization threshold, even when prepared as sub-micron droplets. DFB has a boiling point 
of −1.7°C, significantly lower than other PFCs commonly used in ADV, which may allow 
vaporization at much lower pressures. This could, in turn, significantly decrease the chance 
of unwanted bioeffects due to ultrasound exposure. To date, no study of phase-change 
contrast agents has explored the use of DFB, which is used as a gas in several prototype US 
contrast agent formulations and is similar to MCA gases approved for clinical applications. 
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The aim of this study is to develop a better understanding of the trade-offs inherent in 
choosing a lower boiling-point PFC. The results of this study show the ability to produce 
stable micron and sub-micron lipid-encapsulated phase-change agents that can vaporize at 
lower pressures than similarly-sized emulsions of higher boiling-point PFCs.
MATERIALS AND METHODS
Theory
To investigate whether DFB had potential as a phase-change contrast agent at physiologic 
temperatures, pilot study calculations were performed using the Antoine vapor-pressure 
equation, which was derived from the Clausius-Clapeyron relation by Antoine in 1888 and 
when re-arranged for temperature is expressed as
(1)
where P is pressure, T is temperature and A, B and C are gas-dependent constants observed 
to be valid for a particular temperature range. This equation uses experimental results to 
develop a basic relationship between temperature and pressure as a droplet of a particular 
substance vaporizes. Following reasoning outlined by Rapoport et al. (2009a), a droplet will 
experience an additional pressure due to interfacial surface tension effects, defined as the 
Laplace pressure
(2)
where r is the radius of the droplet, σ is surface tension and Pinside and Poutside represent the 
pressure inside the droplet core and the ambient pressure in the surrounding media, 
respectively. PFCs typically have fairly low surface tension values on the order of 10 mN/m 
at room temperature. Because the Laplace pressure is an inverse function of radius, smaller 
droplets will experience greater pressure. Encapsulating the droplets in a lipid or polymer 
shell stabilizes the droplets from coalescence and alters the interfacial surface tension. 
Depending on the properties of the encapsulating shell, a larger resulting surface tension 
may cause an increase in the pressure exerted, which essentially increases the vaporization 
temperature of the droplet. In designing agents for human medical imaging purposes, the 
ambient pressure may be defined as
(3)
where Patm = 101.325 kPa and Pbody is a representative pressure inside the human body 
(vascular or other). Although intravascular pressure is inherently pulsatile, for the purposes 
of these calculations, an average value of Pbody = 12.67 kPa was used. With a total pressure 
exerted on the droplet of
(4)
The resulting modified Antoine vapor-pressure equation is
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Published surface tensions often vary between 25 mN/m and 50–60 mN/m, depending on 
surfactant properties (Alexandridis et al. 1994; Borden et al. 2004). Although the exact 
surface tension of lipid solutions used in this study were not known, a value near 51 mN/m 
was sufficient for the purposes of these initial calculations in that it provided a Laplace 
pressure near the upper limit of what can be expected. The constants A, B and C were 
gathered from the National Institute of Standards and Technology (NIST) Chemistry 
WebBook (Linstrom and Mallard 2010) for the nearest available temperature range. Figure 1 
shows the relationship between droplet diameter and predicted vaporization temperature for 
octafluoropropane (OFP), decafluorobutane (DFB), dodecafluoropentane (DDFP) and 
perfluorohexane (PFH) (natural boiling points of −37.6°C, −1.7°C, 29°C and 56.6°C, 
respectively). While the constants used are not expected to predict the vaporization 
relationship completely accurately in the desired temperature range, the calculation shows 
that DFB droplets appear to have the potential to remain stable in the 200–600 nm diameter 
range at temperatures just above body temperature. This suggests that they may require a 
small amount of additional energy (such as US) to induce vaporization compared with other 
PFCs, if droplets can be generated stably. Although the temperature required to induce 
vaporization increases substantially for droplets near 200–300 nm in diameter, others have 
shown successful vaporization of droplets through ultrasonic energy at temperatures as 
much as 40°C below their boiling point, as in the case of perfluorohexane droplets 
vaporizing at room and body temperature (Giesecke and Hynynen 2003; Fabiilli et al. 
2010b). According to the estimations, octafluoropropane droplets have the potential to 
remain stable at sizes below 200 nm, although the −37.6°C boiling point presents significant 
production challenges. With a boiling point of −1.7°C, DFB droplet generation can be 
explored at more feasible temperatures.
Ideal gas laws (PV = nRT, where n, P, V and T represent the number of moles of PFC, 
pressure, volume and temperature, respectively) can be used to approximate the expansion 
factor when a liquid undergoes a phase conversion to the gaseous state. Because 
perfluorocarbons are immiscible in the liquid state and have low diffusivity in the gaseous 
state, it is assumed that the number of moles is constant from the liquid phase to the gaseous 
phase (nl = ng). The moles of PFC in the spherical droplet can be computed as
(6)
where rl is the radius of the liquid droplet, ρl is the liquid density and M is the molar mass. 
Substituting this into the ideal gas law and simplifying as a ratio of the gas-phase radius to 
liquid-phase radius gives
(7)
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Expanding with eqn (4) gives
(8)
As rg approaches very large values, the surface tension component becomes negligible.
Decafluorobutane has a molar mass of M = 0.238 kg/mol and at 37°C (310 K) ρl ≈ 1500 
kg/m3. Evaluating eqn (8) with in vivo (Pbody = 12.67 kPa) and in vitro (Pbody = 0 kPa) 
conditions and neglecting surface tension effects reveals that, based on the assumptions 
given, a droplet of DFB can be predicted to expand to an approximate upper limit of 5.2 to 
5.4 times its original diameter once vaporized (neglecting any deviations from ideal gas 
laws). Rearranging eqn (8) such that it is solved for liquid droplet radius becomes
(9)
This allows one, based on ideal gas laws and surface tension effects, to estimate the size of 
the droplet that vaporized to become a bubble of a known size. Evans et al. (2006) show that 
eqn (8) can also be solved for rg, providing a numerically equivalent, though much more 
complex, solution. For the purposes of this study, eqn (9) becomes a more convenient 
solution, as measured bubble sizes are used to estimate originating droplet sizes.
Preparation of micron-sized perfluorocarbon droplets
Lipid thin films were prepared with a lipid composition containing 
dipalmitoylphosphatidylcholine (DPPC), 1-palmitoyl-2-hydroxy-sn-glycero-3-
phosphocholine (LPC) and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (DPPE-PEG-2000) (Avanti Polar Lipids, Alabaster, 
AL, USA). Chloroform (EMD Chemicals; Gibbstown, NJ, USA) was used to dissolve the 
lipids, which were then dried over a stream of nitrogen gas. To remove residual solvent, the 
lipids were stored in vacuo overnight.
The lipid films were rehydrated with approximately 1 mL of (4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid) (HEPES) buffer (pH = 7.4) (Sigma-Aldrich, 
Co., St. Louis, MO, USA) and sonicated for 10 min in a water bath sonicator (Branson 1510; 
Branson Ultrasonic Corporation, Danbury, CT, USA) at 50–60°C. The rehydrated films 
were then subjected to 10 freeze-thaw cycles. The solution was then stirred for 10 min at 
50–60°C. The resulting concentration of the lipid solution was approximately 20 mg/mL.
Three compounds with boiling points above room temperature were selected for comparison 
to decafluorobutane. Perfluoro(2-methyl-3-pentanone) (PFMP), dodecafluoropentane 
(DDFP) and perfluorohexane (PFH) were purchased from FluoroMed (Round Rock, TX, 
USA). Their physical properties are listed in Table 1 (Lide 2010). Each perfluorocarbon was 
added to the lipid solution and multiple extrusions were performed using an Avanti mini-
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extruder (Avanti Polar Lipids, Alabaster, AL, USA) with a 19-mm 1-μm nuclepore 
polycarbonate track-etch membrane filter (Whatman Ltd., Maidstone, Kent, UK) at room 
temperature (25°C). Extrusions were completed after 20 passes through the membrane filter. 
Each sample was placed in a 1.5 mL centrifuge tube. Afterwards, the resulting emulsions 
underwent centrifugation using a Beckman TJ-6 centrifuge (Beckman Coulter, Inc., Brea, 
CA, USA) for 15 min at 1000 rpm. The emulsions were stored immediately in the 
refrigerator (4°C).
Preparation of micron-sized decafluorobutane droplets
For DFB droplets (physical properties found in Table 1), the same lipid formulation was 
prepared. DFB (FluoroMed, Round Rock, TX, USA) gas was condensed over dry ice 
followed by storage into a 2 mL glass vial and crimped. Samples were then mixed with the 
corresponding lipid solution and extruded through a 13 mm diameter syringe holder 
equipped with a 1-μm Nuclepore polycarbonate track-etch membrane filters (Whatman Ltd., 
Maidstone, Kent, UK) in a −20°C freezer to maintain the DFB in the condensed state while 
at the same time being careful not to freeze the solution. DFB emulsions were then sealed in 
a 2 mL vial and stored in a 4°C refrigerator prior to testing.
Preparation of sub-micron-sized decafluorobutane droplets
Sub-micron droplets were prepared using a newly developed condensation method whereby 
microbubbles of desired size were prepared followed by pressurization and condensation to 
generate the DFB-condensed droplets (patent pending). The volumetric change produced for 
each condensed bubble resulted in a sample of liquid DFB droplets with a majority in the 
sub-micron range.
Sizing droplets
Perfluorocarbon emulsions were prepared for sizing on a Malvern Nano ZetaSizer (Malvern 
Instruments Ltd., Malvern, Worcestershire, UK). The ZetaSizer was set to automatically 
detect up to three local distribution peaks (multi-modal). Briefly, a 150 μL sample was 
introduced into a 12 mm disposable square polystyrene cuvette and 1 mL of HEPES buffer 
was added. The associated software was utilized to help identify the average sizes of the 
droplets along with the dispersity and size distributions.
Experimental apparatus
A water bath constructed of acrylic was mounted on top of an inverted microscope 
(Olympus IX71) and interfaced with a high-speed camera (FastCam SA1.1, Photron USA, 
Inc., San Diego, CA, USA) to capture monochrome videos and still images of particles and 
microbubbles (Fig. 2). A ×100 water immersion objective with a working distance of 1.5 
mm was used to provide image magnification. The optical resolution of the system was 
measured to be approximately 0.5 μm, as determined by a polystyrene latex sphere 
resolution test (Ted Pella, Inc., Redding, CA, USA). Baseline water oxygen saturation was 
measured to be 5 parts per million (PPM) at 37°C, as measured by a chemical test kit 
(Oxygen CHEMets, CHEMetrics, Inc., Calverton, VA, USA). In the case of degassed 
experiments, an in-line degasser was allowed to operate until the water oxygenation in the 
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water tank measured less than or equal to 1.5 PPM. The water bath was passively heated to a 
consistent 37°C by heating water in an auxiliary tank and continuously pumping it through 
copper coils lining the main tank such that vibration in the water bath was minimized. The 
temperature of the auxiliary tank was adjusted until the desired temperature of the water in 
the experiment region of the main tank along with any additional light-heating was reached. 
The dropletsolution was pumped through a nearly optically and acoustically transparent 
cellulose tube with a 200 μm inner diameter (Spectrum Labs, Inc., Greensboro, NC, USA) 
using a custom-built manual injector allowing for precise administration of the droplets into 
the field of view. A 3-axis micropositioner (MMO-203; Narishige Group, East Meadow, 
NY, USA) was utilized to manipulate the sample holder and, therefore, the droplets/bubbles 
in the field of view. By this means we were able to locate and manipulate droplets to stay 
on-screen throughout the test and track the resulting bubbles.
Acoustics
A spherically focused 5 MHz transducer with a focal length of 3.8 cm (IL0506HP; Valpey 
Fisher Corp., Hopkinton, MA, USA) was used to insonify droplet samples. The transducer 
had −6 dB beam widths of 0.7 mm laterally and 13.2 mm axially for peak positive pressure, 
while widths were 1.3 mm laterally and 22.8 mm axially for peak negative pressure. 
Waveforms were constructed using an arbitrary waveform generator (AWG 2021; 
Tektronix, Inc., Beaverton, OR, USA), which allowed for adjustment of the transmission 
waveform pulse length and amplitude. A manually-triggered signal of adjustable amplitude 
was used for these experiments consisting of a 10-cycle sinusoid at 5 MHz resulting in a 
total insonification time of 2 μs. A synchronization pulse from the waveform generator was 
relayed to the high speed camera to trigger a marker with the acoustic pulse on the digital 
video. The waveform from the function generator was amplified approximately 60 dB using 
an RF amplifier (A500; ENI, Rochester, NY, USA) to excite the transducer. For optical-
acoustic alignment, the transducer focus was matched with the optical focus by positioning 
the tip of a needle hydrophone (HNA-0400; Onda Corp., Sunnyvale, CA, USA) in center of 
the microscope field of view. The transducer was then calibrated at focus over the range of 
amplitudes used so that the pressure exerted on the droplets in the field of view was known.
Analysis of images
Still images and videos were captured and stored on a computer using proprietary camera 
software (PFV; Photron USA, Inc., San Diego, CA, USA). The software was set to start 
recording just before the manually-triggered ultrasound signal so that the transition from 
droplet to bubble could be observed continuously. Image analysis was performed on the 
recordings (ImageJ; NIH, Bethesda, MD, USA) to calculate the diameter of the droplets and 
resulting bubbles.
Vaporization threshold of individual PFC droplets and subsequent diameter
The vaporization threshold of individual PFC droplets was performed by first venting the 
undiluted samples with a 20-gauge needle and then diluting in phosphate-buffered saline 
(PBS) until only one to two droplets were visible on screen at any particular time after 
injection into the cellulose tube. This typically ranged from 1–20 μL/mL PBS and depended 
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on the concentration of larger droplets present in the original sample. In the degassed 
experiments, the PBS, which normally measured approximately 6 PPM oxygen, was placed 
under vacuum prior to dilution until the oxygenation measured less than or equal to 3 PPM 
so that both the water tank and diluent were degassed. As larger PFC droplets tended to flow 
near the bottom of the cellulose tube due to weight and because the largest droplet on screen 
vaporizes with the least amount of energy input, there was little chance of out-of-focus 
droplets, which tended to be very small and toward the top of the tube, interfering with 
vaporization threshold determination. The droplets were held on screen with the position 
manipulator and ultrasound pressure in the form of a 2 μs pulse at 5 MHz was increased in 
incremental steps of approximately 0.115 MPa with 1–2 s of rest time between each trigger. 
The earliest pressure that induced observed vaporization was recorded to correlate to droplet 
diameter and the tube was shifted by micro-manipulator so that the focus was fully on the 
resulting bubble diameter. This diameter of the bubble was observed and measured over 
several seconds to capture any phenomena. For analysis, the pressure that induced 
vaporization was converted to mechanical index (MI), defined as:
(10)
When switching between samples, the cellulose tube was either re-made with new tubing or 
flushed with a sequence of: (1) 1 mL 95% ethanol, (2) 3 mL of air and (3) 1mL de-ionized 
water and for tests involving larger droplets inspected optically to ensure no droplets were 
present in the remaining fluid.
Sub-micron droplet vaporization threshold and estimation of vaporized droplet size
Due to the fact that droplets smaller than 1 μm challenged the resolution capabilities of the 
experimental setup, the approach to sub-micron droplet vaporization differed from the 
individual PFC droplet approach. Samples generated by the microbubble condensation 
method were diluted to approximately 300 μL/mL PBS to increase the number of viable 
droplets in the field of view. Sample sizing was performed by dynamic light scattering to 
ensure they consisted of sub-micron sized droplets only. Other studies have shown that large 
outliers, which would likely vaporize first, could impact the vaporization threshold of 
remaining droplets (Lo et al. 2007). After optical verification that no micron-sized droplets 
were present in the sample, the top of the cellulose tube was brought into focus to verify that 
no bubbles were present prior to the US energy. Samples were insonified using a 5 MHz 
sinusoid with a pulse length of 2 ms and the pressure increased until a significant number of 
bubbles of sizes less than 5 μm were consistently produced. The pressures used by this 
method, therefore, are not direct vaporization thresholds, but are rather “activation” values 
that are seen to vaporize the majority of the content in the bulk sample so that its contents 
can be measured. By the ideal gas law estimations delineated above, bubbles with diameters 
of 5 μm or less should result from droplets originally sized less than 1 μm. The resulting 
bubbles floated to the top of the tube after the acoustic pressure was applied and were 
“scrolled” through using the volume position manipulator. Bubbles were counted, measured 
and correlated to sizing results as indirect evidence of sub-micron droplet vaporization.
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Several hundred droplets of DFB, DDFP, PFMP and PFH were insonified with varying 
ultrasound pressure at 5 MHz. A total of 153 successfully vaporized droplets across all PFCs 
investigated were evaluated for the relationship between initial diameter and pressure 
required for vaporization, as well as resulting bubble characteristics.
Droplet sizing and optical verification
DFB, DDFP, PFMP and PFH extrusion through membrane filters resulted in sub-micron and 
micron-sized droplets. As the upper measurement limit of the Malvern ZetaSizer was 6 μm 
in diameter, the range of droplets larger than those measured was not captured, but the 
largest DFB droplet observed optically after being heated to 37°C over all tests performed 
was measured to be approximately 13 μm in diameter. DFB droplet generation by the 
microbubble condensation method resulted in primarily sub-micron droplet distributions 
with diameter peaks near 300 nm and a range typically from 200–600 nm (Fig. 3). 
Information about initial droplet concentration was not obtained through the sizing 
techniques used, but did not affect the results, as each sample was diluted to an optimal 
concentration for each test.
Vaporization threshold for individual perfluorocarbon droplets
Through high-dilution, individual PFC droplets were exposed to ultrasound peak negative 
pressures ranging from 1.43 MPa to 4.97 MPa during the course of the 2 μs signal, or a 
mechanical index between 0.64 and 2.22. Vaporization of DFB, DDFP and PFMP droplets 
in the 1–30 μm diameter range was recorded optically and the vaporization threshold plotted 
as a function of initial droplet diameter (Fig. 4). PFH droplets, the largest of which measured 
approximately 9 μm, were unable to be vaporized at the pressures used for this study and are 
not represented in the figure. Studies by others have shown that PFH can be vaporized in 
other test conditions and size ranges. A minimum of 15 droplets of each PFC were used to 
curve-fit threshold values across the size range. The average diameter of both DFB and 
DDFP droplets vaporized in this set of experiments was 5 ± 3 μm while PFMP droplets 
measured an average of 14 ± 6 μm. As demonstrated by many studies, the vaporization 
threshold appeared to increase as the droplet diameter decreased. Curves that produced the 
best fits for the vaporized droplets were logarithmic, resulting in R2 values of 0.84, 0.84 and 
0.74 for DFB, DDFP and PFMP, respectively. For the smaller droplet sizes observed, the 
pressure required to vaporize DDFP and PFMP was approximately 50% and 75% more than 
that required for DFB, respectively. As droplet size increased, the difference in activation 
pressure compared with DFB decreased, reducing to only 30% and 60% more pressure for 
DDFP and PFMP, respectively, for droplets of approximately 10 μm.
All micron-sized droplets of DFB were seen to vaporize at a MI lower than 1.5, while 
comparable pressures were only able to vaporize droplets greater than 10 μm in size for both 
comparison PFCs. The relatively short 2 μs was sufficient to induce vaporization for all 
PFCs other than PFH. Additionally, bubbles created by vaporization of DFB droplets were 
subjected to secondary pulses administered several seconds after formation, during which no 
instances of bubble destruction were observed.
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Observation of resulting bubble diameter in gassed and de-gassed experiments
The experimental set-up allowed for verification of specific droplet vaporization, so 
resulting bubbles could be correlated directly to the initial droplet diameter. This continuous 
observation allowed for noting of any effects that occurred subsequently to vaporization. 
Ideal gas laws at these initial sizes predict that the phase-change should result in a gas 
bubble approximately 5.2–5.4 times larger than the original droplet diameter. During the 
course of the vaporization thresholds in the un-degassed experimental setup, it was noticed 
that the resulting bubbles tended to be much larger than the predicted size. Because the 
bubbles were continually observed in an extremely dilute state, it could be confirmed that 
this did not occur due to bubble coalescence after droplet vaporization. The experiment was 
repeated in a degassed experimental set-up for both DFB and DDFP and the resulting 
diameter plotted as a function of initial diameter (Fig. 5). The results in the un-degassed 
experiment follow an approximately linear fit (R2 = 0.84), while the degassed results show a 
strongly linear fit (R2 = 0.98). The average un-degassed expansion over 46 observed 
droplets was 10 ± 2 times the original diameter, while the degassed experiment resulted in 
an average expansion over 37 droplets of 6 ± 1 times the original diameter. In both cases the 
increase in expansion beyond the predicted values did not appear correlated to initial droplet 
diameter. Two videos of individual bubbles observed over a longer time period were 
analyzed for both degassed and un-degassed setups. Figure 6 shows examples of the 
observed phenomenon in both scenarios. The bubbles in the un-degassed experiments grew 
an average of 22% of their original observed diameter over the experiment duration, while 
those in the degassed experiments only grew an average of 4% over the same time period.
Vaporization of sub-micron decafluorobutane droplets
For vaporized droplets produced by microbubble condensation, an average MI of 1.71 (a 
peak negative pressure of 3.82 MPa) consistently produced microbubbles with sizes 5 μm or 
smaller. Immediately prior to vaporization, no droplets or bubbles were present in the frame. 
Once ultrasound pressure was applied, droplets were immediately present (Fig. 7). In many 
instances, bubbles larger than 5 μm were observed that did not correlate well to the sizing 
results. Observing the resulting bubbles over several seconds in multiple tests showed that 
bubbles resulting from this droplet generation technique were much more prone to 
coalescence than for droplets made by extrusion, potentially due to the difference in lipid 
concentration between the two methods, which could account for the presence of larger 
bubbles. The resulting measured bubble diameters within optical resolution produced over 
several tests with the same conditions (outliers greater than 5 μm excluded), had a mean of 2 
± 1 μm (N = 148).
DISCUSSION
In this study, the vaporization threshold for micron and sub-micron sized decafluorobutane 
droplets was examined in contrast to other commonly studied perfluorocarbons to determine 
efficacy as a candidate phase-change contrast agent in applications such as intra-tumoral 
deposition and imaging. The results show that lipid-encapsulated DFB droplets can be 
successfully manufactured in the micron and sub-micron range by membrane extrusion. The 
additional pressure exerted by the lipid membrane on the liquid droplet was proven 
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sufficient to keep small-sized droplets in solution at physiologically relevant temperatures 
prior to vaporization by additional energy input, in this case by ultrasound at clinically 
relevant frequencies and pressures.
These results serve as an early indicator of the high potential of DFB as a future phase-
change contrast agent, especially for extravascular applications. The curve fit to the 
thresholds of individual droplets predicts an increasing gap in the energy difference needed 
to vaporize DFB when compared with its higher-boiling-point counterparts as the droplet 
diameter decreases. For example, a 300 nm droplet of DDFP with the same short waveform 
and frequency used in these tests is predicted by the curve fits to require approximately a MI 
of 2.69 to vaporize, while a DFB droplet is only predicted to require a MI of 1.78, below the 
current clinical limit of 1.9 for diagnostic imaging. The demonstrated threshold values for 
DDFP seem to be consistent within the range reported by others in similar experiments, 
although longer pulse lengths were used in most other studies. Lo et al. (2007) as well as 
others, demonstrated that the vaporization threshold for perfluorocarbon droplets could be 
lowered by increasing signal pulse length and by increasing US frequency used. It is 
possible that the same techniques could be applied to further lower the vaporization 
threshold for DFB to values below the currently presented ones.
The pulse lengths used in this study were relatively short, so that the temperature increase 
induced by the acoustic signal can be assumed to be negligible. This implies that the 
thresholds observed by this study were probably due mostly to mechanical effects such as 
those outlined by Kripfgans et al. (2004). Whether or not the curves fit to vaporization 
thresholds accurately predict the pressure required for submicron-sized droplets of both 
DDFP and DFB necessitates further studies. It can be reasonably argued that as the diameter 
of the droplet is reduced into the nanometer range, the observed effects at the micrometer 
scale will not predict those at the nanometer scale.
The observation that bubbles tended to be larger than anticipated in a gas-saturated 
environment matches that of Kripfgans et al. (2000). Their study posits that the resulting 
bubbles may expand due to absorption of dissolved gases present in the host fluid, which is 
in line with our observation of gradual bubble growth over a several-second time period. We 
were able to optically observe the transition of individual droplets into the resulting bubbles 
and confirm that almost immediately after vaporization was induced, the resulting bubble 
was larger than that predicted by ideal gas laws. The optical set-up also allowed for 
confirmation that bubbles were not the result of the effects of coalescence. In the case of un-
degassed fluid, the resulting bubble averaged an expansion factor of 10 over initial droplet 
size, while in the degassed set-up the expansion factor was 6. We hypothesize that the 
expansion factor observed with the degassed set-up, which was higher than ideal gas 
predictions, was likely due to the diffusion of dissolved gas still present (oxygenation 
measured at 1.5 PPM). In both cases, the measurements were made within seconds after 
vaporization and even after this measurement the bubbles appeared to still be growing in 
diameter gradually. We estimated that the growth rate was four to five times as quick in the 
case of un-degassed fluid, which explains the higher variation in the measured expansion 
factor (some may have had more time to expand than others prior to measurement). A recent 
experimental study by Wong et al. (2011) used ultra-high speed imaging to show that bubble 
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evolution on a very short timescale appears to occur in several stages immediately after 
vaporization and plateaus at an expansion factor close to the theoretical value within 
approximately 150 μs independent of droplet size. The presence of a lipid shell could serve 
to damp the intake of dissolved gases and result in gradual growth over a much longer 
period after vaporization, although determining whether bubbles approach a maximal or 
steady-state size will require future studies. The initial results suggest that ADVagents may 
experience a similar effect post-vaporization with regard to gas-saturation levels as Kwan 
and Borden (2010) recently modeled for gas-filled MCAs. In applications where an upper 
limit on bubble size is essential, thorough studies of the effect of local gas-saturation will be 
needed to ensure that the bubble does not expand to beyond the required size and cause 
unwanted effects. Although some tumors are known to be hypoxic, they cannot be assumed 
to be gas-free and, therefore, an expansion beyond that predicted by ideal gas laws may be 
observed in practice.
The results produced using the higher-concentration sub-micron droplet solutions provide 
promising evidence that vaporization of sub-micron sized DFB droplets is, in fact, feasible 
at relevant pressures for diagnostic imaging. Bubbles that most likely resulted from sub-
micron droplets of DFB were produced using a mechanical index of 1.71 and a single pulse 
of only 2 μs, which would also avoid heating-based bioeffects. With such short pulse 
lengths, it is unlikely that these bubbles resulted from fractioning of larger bubbles or any 
similar effects.
As a second step of indirect proof for sub-micron droplet vaporization, the bubble 
measurements obtained from this set of experiments were used to estimate the size of the 
originating droplets for comparison with the initial particle sizing. The experimentally 
observed expansion factor of 6 for droplets in the micrometer range was not used for this 
estimation due to the assumption that surface-tension effects will become much more 
dominant for droplets in the nanometer range. It also cannot be assumed that the observed 
expansion due to ambient dissolved gas will affect the expansion of nanometer-sized 
droplets as it does micron-sized droplets due to the significantly increased internal pressure 
of the droplet. Therefore, ideal gas law estimations are preferable in this size range. 
Equation (9) was evaluated for 148 measured bubbles with the parameters Pamb = 101.325 
kPa and a surface tension of σ = 30 mN/m, which is suitable for the lipid solution used for 
these droplets. A histogram of the estimated droplet sizes that produced the measured 
bubbles (Fig. 8) shows that the peak estimated droplet sizes occurred in the 300–350 nm bin, 
which matches extremely well with the original sizing results produced by dynamic light 
scattering (Fig. 3). The histogram appears to be skewed to the right of the central peak, 
which may be anticipated due to the stochastic nature of droplet vaporization, even at 
sufficient pressures to vaporize droplets smaller than 350 nm, droplets larger than 350 nm 
will vaporize with greater efficiency. The curve fits for DFB in the micron-sized droplet 
experiments predict a MI of 1.78 for vaporization of 300 nm droplets, which is in good 
agreement with the observed MI of 1.71 necessary to vaporize content near this size. The 
lipid formulations varied significantly between the two generation methods and so 
vaporization thresholds may be lower for these nanometer-scale droplets than the curve-fits 
Sheeran et al. Page 13













predict. These observations taken together provide strong evidence that vaporization of sub-
micron DFB droplets can be achieved with feasible diagnostic imaging pressures.
Evaluating eqn (9) for differing parameter values reveals the effect of scaling on the 
interplay of ambient pressure and Laplace pressure (Fig. 9). For droplets in the nanometer 
size range, surface tension effects become dominant and the largest expansion is predicted 
by the lowest surface tension. A transition occurs at the low micrometer range, resulting in 
ambient pressure becoming the dominant effect on expansion for larger droplets. The largest 
expansion in this region can be predicted by the lowest ambient pressure. Additionally, a 
sharp decline in the expansion factor is observed as droplet sizes approach the lower 
nanometer range. This can have fundamental implications in design of phase-change 
contrast agents for purposes of extravasation. To take advantage of the EPR effect, droplets 
of 100–200 nm in size would be ideal, resulting in enhanced intratumoral diffusion. 
However, once these droplets are vaporized, they may only increase by a factor of 2.5–3.5 
times the original diameter, resulting in bubbles on the order of 250–700 nm. While bubbles 
of this size may still be useful for cavitation-based effects and enhancing thermal therapy or 
drug delivery, they are much smaller than preferable for diagnostic imaging, where bubbles 
are ideally on the order of 1–5 μm. Through post-extravasation droplet/bubble coalescence, 
these may still provide increased echogenicity, although no studies have characterized to 
what degree this type of coalescence may actually occur in vivo. Therefore, there exists a 
design trade-off in echogenicity and droplet diffusivity. Droplets near 250–350 nm in size 
will likely still diffuse into interstitial space due the EPR effect and will produce bubbles on 
the order of 1 μm or greater, providing ideal image enhancement for applications such as 
early tumor detection and real-time confirmation of targeted therapeutic delivery.
In all of the tests on DFB droplets, short pulse lengths appeared to be adequate to activate 
both micron and sub-micron sized droplets at clinically relevant pressures. In practice, it 
may be possible to further reduce the likelihood of unwanted bioeffects by creating a custom 
activation/imaging pulse. A brief “activation” pulse could be delivered at the front-end of 
each frame acquisition followed by gathering of image lines at a much lower MI, rather than 
imaging at the “activation” MI for the entirety of the imaging session. This is similar to 
commonly-employed functional diagnostic imaging schemes centered on contrast agent 
perfusion imaging in kidney and tumor vasculature, where a high-MI pulse is used to 
destroy contrast agents and lower-MI pulses are used to image the subsequent vascular 
reperfusion.
CONCLUSION
It has been shown that decafluorobutane can be successfully generated as lipid-encapsulated 
micron and sub-micron sized droplets that remain stable at physiologic temperatures. Most 
studies of phase-change contrast agents to date have chosen PFCs that are stable at room 
temperature, presumably due to simplicity of droplet generation. This study is the first, to 
the knowledge of the authors, which has explored the use of lower boiling-point PFCs by 
using shell encapsulation to produce stable liquid droplets from PFCs that are normally gas 
at room and body temperature. Further investigations are needed to characterize the stability 
of DFB droplets in vitro and in vivo as well as potential bio-effects in vivo. DFB-based 
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phase-change contrast agents show significant potential for applications such as intra-
tumoral deposition of chemotherapeutics and the imaging of interstitial space.
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Predicted vaporization temperature of lipid-encapsulated perfluorocarbons based on Antoine 
vapor pressure equation. As droplet diameter decreases, the temperature required to vaporize 
increases exponentially.
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Experimental set-up for vaporization of perfluorocarbon (PFC) droplets.
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Dynamic light scattering sizing results for a decafluorobutane (DFB) droplet sample 
produced by microbubble condensation.
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Vaporization threshold of individual droplets as a function of initial droplet diameter for 
decafluorobutane (DFB), dodecafluoropentane (DDFP) and perfluoro(2-methyl-3-
pentanone) (PFMP) droplets sonicated at 5 MHz with a 2 μs pulse. The curves fit to the 
measurement points are MIDFB = −0.18ln(d) +1.57, MIDDFP = −0.34ln(d) + 2.28 and 
MIPFMP = −0.50ln(d) + 3.03, where d is the droplet diameter in μm.
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Bubble size post-vaporization for both dodecafluoropentane (DDFP) and decafluorobutane 
(DFB) shows a dependence on the dissolved gas level of the local fluids. Bubbles in a 
degassed environment showed resulting sizes nearer to those predicted by ideal gas laws, 
while normal tests resulted in bubbles significantly larger than the predicted size.
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Bubble growth from individual droplets observed over several seconds. (a) through (d) show 
an ~7 μm droplet in a normal test environment growing to a bubble near 52 μm after 6 s of 
observation. In a test using degassed fluids, (e) through (h) show an ~8.5 μm droplet 
growing to approximately 50 μm after the same time period. Note: in (a) and (e), other 
spherically shaped particles are out-of-focus debris on the cellulose tube, not viable 
perfluorocarbon (PFC) droplets.
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Still-frame images before and immediately after submicron decafluorobutane (DFB) sample 
was subject to an ultrasound pulse at a mechanical index (MI) of 1.71.
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Histogram of estimated size of droplets resulting from observed bubbles 5 μm or smaller (N 
= 148).
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Effect of droplet size on expansion factor according to ideal gas laws with Laplace pressure 
included. Calculations are presented for two variations of both ambient pressure (Pin vitro = 
Patm; Pin vivo = Patm + Pbody) and surface tension (σ1 = 30 mN/m; σ2 = 51 mN/m). Droplets 
on the order of 10 mm can be expected to expand less in vivo than in vitro regardless of 
surface tension, while droplets 500 nm or less will expand less at higher surface tension 
values.
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